Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Wednesday, January 6

Antibody-based strategies in HIV therapy

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

EUA for COVID-19 Vaccines and Treatments in the Philippines

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Leronlimab and Long-Haulers

Latest Publication Leronlimab Blocks Breast Cancer

CytoDyn Q&A with CEO Nader Pourhassan - January 26

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

Apr 06, 2020 6:00am EDT

CytoDyn CEO Dr. Pourhassan Appearance on Fox Business Network Rescheduled to April 8 Same Time (11am PT); CytoDyn will Reveal Today the Name of the Hospital and the Physician who Treated 10 Patients During an Interview on Seattle-Affiliate of CBS News which Will Air Between 5-6:30 p.m. PT

Apr 03, 2020 1:48pm EDT

CytoDyn Files Request with FDA for Preliminary Meeting for Breakthrough Therapy Designation for Leronlimab in the Treatment of Cancer

Apr 03, 2020 6:15am EDT

CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill COVID-19 Patients and Express Appreciation for a Special Hospital, Physician, and Medical Team Who Treated These Patients

Apr 03, 2020 6:00am EDT

Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients

Apr 02, 2020 6:00am EDT

CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks

Apr 01, 2020 6:00am EDT

CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

Mar 31, 2020 6:15am EDT

FDA Clears CytoDyn’s Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

Mar 31, 2020 6:00am EDT

Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

Mar 30, 2020 6:00am EDT

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

Mar 27, 2020 6:15am EDT
RSS
  • Prev
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...33
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap